Search research articles
Contact Us
Filters
Showing results (41-50 of 57) with videos related to
Page
of 6
Sort By:
ESMO Open
|
June 22, 2026
Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC)
C Parisi, M Banini, F Mantuano, et al.
ESMO Open
|
June 4, 2024
Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort
Q D Thomas, X Quantin, P Lemercier, et al.
ESMO Open
|
April 23, 2024
Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort
J Remon, E Auclin, L Zubiri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)
A Martinez-Marti, E Felip, J Matito, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 2, 2023
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
J Remon, B Besse, S Ponce Aix, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 4, 2024
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
M F Mosele, C B Westphalen, A Stenzinger, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 1, 2025
Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group
E Xenophontos, N Giaj Levra, V Durieux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 21, 2025
Corrigendum to "Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group": [Ann Oncol 35 (2024) 588-606]
M F Mosele, C B Westphalen, A Stenzinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 28, 2020
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
F Mosele, J Remon, J Mateo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 30, 2026
Lung cancer brain metastases management at the dawn of personalized medicine: are we ready to break the barriers?
A Mavrikios, M Bortolot, C Le Péchoux, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 57) with videos related to
Sort By:
Page
of 6
ESMO Open
|
June 22, 2026
Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC)
C Parisi, M Banini, F Mantuano, et al.
ESMO Open
|
June 4, 2024
Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort
Q D Thomas, X Quantin, P Lemercier, et al.
ESMO Open
|
April 23, 2024
Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort
J Remon, E Auclin, L Zubiri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)
A Martinez-Marti, E Felip, J Matito, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 2, 2023
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
J Remon, B Besse, S Ponce Aix, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 4, 2024
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
M F Mosele, C B Westphalen, A Stenzinger, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 1, 2025
Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group
E Xenophontos, N Giaj Levra, V Durieux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 21, 2025
Corrigendum to "Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group": [Ann Oncol 35 (2024) 588-606]
M F Mosele, C B Westphalen, A Stenzinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 28, 2020
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
F Mosele, J Remon, J Mateo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 30, 2026
Lung cancer brain metastases management at the dawn of personalized medicine: are we ready to break the barriers?
A Mavrikios, M Bortolot, C Le Péchoux, et al.
Page
of 6